Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization (NCT07642960) | Clinical Trial Compass
RecruitingNot Applicable
Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
Vietnam51 participantsStarted 2026-04-01
Plain-language summary
The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization.
The main questions it aims to answer are:
Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients?
Participants will:
Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms.
Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age over 18 years.
* Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
* Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
* Agreement to participate in the study and ability to comply with outpatient follow-up requirements
Exclusion Criteria:
* Pregnant or breastfeeding women.
* History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
* Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease.
* Active ocular infection or acute conjunctivitis at the time of enrollment.
* Persistent corneal epithelial defect or delayed corneal epithelial healing.
* History of ocular surgery within 3 months before study enrollment.
* Corneal neovascularization associated with uncontrolled secondary glaucoma.
* Inability or unwillingness to comply with study treatment or follow-up visits.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percentage reduction in corneal neovascularization area at 12 months